EstechPharma Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.
December 11, 2016
Share
EstechPharma Co., Ltd. (KOSDAQ:A041910) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million pursuant to a trust contract with Korea Investment & Securities Co., Ltd. The purpose of the share repurchase program is to improve shareholder value and to stabilize stock price. The share repurchase program is valid until June 12, 2017. As on December 11, 2016, the company had 112,171 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.
Polaris AI Pharma Corp, formerly ESTECHPHARMA CO., LTD, is a Korea-based company engaged in the development and manufacture of pharmaceuticals. The Company is engaged in the manufacture and sale of peptic ulcer medicine, diabetes medicine, central nervous system medicine, antispasmodics, antipyretics, and painkillers. It has a research and development institute that develops active pharmaceutical ingredients. The company sells its products in domestic and international markets.
POLARIS AI PHARMA CORP. 
